


## PG-11047 tetrahydrochloride

<b>Cat. No.:</b>	HY-16394		
<b>CAS No.:</b>	206991-64-2		
<b>Molecular Formula:</b>	C <sub>14</sub> H <sub>36</sub> Cl <sub>4</sub> N <sub>4</sub>		
<b>Molecular Weight:</b>	402.27		
<b>Target:</b>	Others		
<b>Pathway:</b>	Others		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : ≥ 30 mg/mL (74.58 mM)  
 \* "≥" means soluble, but saturation unknown.

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.4859 mL	12.4295 mL	24.8589 mL
	5 mM	0.4972 mL	2.4859 mL	4.9718 mL
	10 mM	0.2486 mL	1.2429 mL	2.4859 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

PG-11047 (CGC-11047), a polyamine analogue, is a nonfunctional competitor of the natural polyamine spermine. PG-11047 has broad spectrum anticancer activities<sup>[1][2]</sup>.

### REFERENCES

[1]. Wen-Lin Kuo, et al. A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047. BMC Med. 2009 Dec 14;7:77.

[2]. Murray Stewart T, et al. A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma. Cancer Chemother Pharmacol. 2021 Jan;87(1):135-144.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA